Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Belimumab. A new targeted therapeutic option for lupus erythematosus].

× No keyword cloud information.

6 in total

1. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Authors: Richard Furie; Michelle Petri; Omid Zamani; Ricard Cervera; Daniel J Wallace; Dana Tegzová; Jorge Sanchez-Guerrero; Andreas Schwarting; Joan T Merrill; W Winn Chatham; William Stohl; Ellen M Ginzler; Douglas R Hough; Z John Zhong; William Freimuth; Ronald F van Vollenhoven
Journal: Arthritis Rheum Date: 2011-12

2. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors: Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal: Lancet Date: 2011-02-04 Impact factor: 79.321

[Belimumab. A new targeted therapeutic option for lupus erythematosus].

1. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

2. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Review 3. Clinical outcome measures for cutaneous lupus erythematosus.

4. An update on belimumab for the treatment of lupus.

Review 5. Advances in drug therapy for systemic lupus erythematosus.

6. Belimumab: First targeted biological treatment for systemic lupus erythematosus.